Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antihypertensive Therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    288 result(s) found for: Antihypertensive Therapy. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-004933-32 Sponsor Protocol Number: km 55/2004 – LORISTAH/CZ Start Date*: 2005-03-04
    Sponsor Name:KRKA, d. d., Novo mesto
    Full Title: Efficacy and safety of Lorista and Lorista H in the treatment of mild to moderate arterial hypertension
    Medical condition: mild to moderate hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-004809-58 Sponsor Protocol Number: HEBRO-001 Start Date*: 2019-04-04
    Sponsor Name:Institute for study, research, education and therapy of vascular, heart, brain and kidney nosologies (I.N.A.K.E.N)
    Full Title: Comparative study of eplerenone-based treatment strategy versus irbesartan-based blood pressure lowering in obese hypertensive patients (HEBRO Study)
    Medical condition: Primary Hypertension and Obesity
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006981-40 Sponsor Protocol Number: hypertension2006-006981-40 Start Date*: 2007-05-03
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust jointly with University of Cambridge
    Full Title: Does the underlying haemodynamic abnormality determine response to antihypertensive therapy in patients with hypertension?
    Medical condition: Essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004254 Benign essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003535-20 Sponsor Protocol Number: CS8635-A-E303 Start Date*: 2009-04-07
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: A RANDOMISED, DOUBLE-BLIND, ADD-ON STUDY OF HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE HYPERTENSION NOT ACHIEVING TARGET BLOOD PRESSURE ON OLMESARTAN MEDOXOMIL/AMLODIPINE FIXED DOSE CO...
    Medical condition: Essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed) BE (Completed) ES (Completed) AT (Completed) CZ (Completed) DK (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-000020-32 Sponsor Protocol Number: CV131-176 Start Date*: 2005-02-16
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension
    Medical condition: Severe Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006090-25 Sponsor Protocol Number: GARBK8273 Start Date*: 2012-03-06
    Sponsor Name:Tartu Ülikooli kardioloogiakliinik
    Full Title: The Impact of Heart Rate on Central Hemodynamics of Antihypertensive Therapy
    Medical condition: Patients with dual chamber (atrium and ventricle) cardiac pacemaker placed due to sick sinus syndrome (at least 1 month after implantation)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10053103 Heart rate and pulse investigations HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005344-95 Sponsor Protocol Number: 3004 Start Date*: 2012-06-15
    Sponsor Name:Steno Diabetes Center
    Full Title: Time course of the blood pressure lowering effect of liraglutide therapy in type 2 diabetes
    Medical condition: type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000631-25 Sponsor Protocol Number: 2007-000631-25 Start Date*: 2010-06-08
    Sponsor Name:KAROLINSKA INSTITUTET
    Full Title: THE ANTITTHROMBOTIC EFFECTS OF DOXAZOSIN AND RAMIPRIL IN ESSENTIAL HYPERTENSION
    Medical condition: ESSENTIAL HYPERTENSION
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000690-34 Sponsor Protocol Number: 0954A-327 Start Date*: 2007-05-29
    Sponsor Name:Merck Sharp & Dohme OÜ
    Full Title: A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With ...
    Medical condition: Essential Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) FI (Prematurely Ended) LT (Prematurely Ended) HU (Completed) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002544-40 Sponsor Protocol Number: 5866 Start Date*: 2014-10-29
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: THE TREATMENT OF HYPERTENSION ASSOCIATED WITH SEVERE PREECLAMPSIA. A RANDOMIZED CONTROLLED TRIAL OF URAPIDIL VERSUS NICARDIPINE. The URANIC trial.
    Medical condition: Hypertension associated with severe pre eclampsia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002442-19 Sponsor Protocol Number: 502.480 Start Date*: 2005-08-31
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12...
    Medical condition: essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) IE (Completed) DK (Completed) FI (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000895-16 Sponsor Protocol Number: SPP100C2201 Start Date*: 2005-04-01
    Sponsor Name:Novartis Ireland Ltd
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihyp...
    Medical condition: patients with hypertension, Type 2 DM and proteinuria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) SK (Prematurely Ended) DK (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003876-37 Sponsor Protocol Number: CS866CM-B-E301 Start Date*: 2006-11-28
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy
    Medical condition: Essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001898-25 Sponsor Protocol Number: DAR-311 Start Date*: 2006-09-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Effica...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004393-33 Sponsor Protocol Number: ID-080A301 Start Date*: 2018-09-13
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: Multi-center, blinded, randomized, parallel-group, Phase 3 study with aprocitentan in subjects with Resistant Hypertension (RHT)
    Medical condition: Resistant Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10020783 Hypertension not adequately controlled LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) BE (Completed) FI (Completed) CZ (Completed) HU (Ongoing) NL (Completed) PL (Completed) DK (Completed) GR (Completed) LT (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000165-23 Sponsor Protocol Number: INFORM Start Date*: 2016-10-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: ComparIsoN oF Optimal Hypertension RegiMens (Part of the Ancestry Informative Markers in Hypertension (AIM HY) Programme – AIM HY-INFORM)
    Medical condition: Cardiovascular Hemodynamics
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10005727 Blood pressure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-000447-28 Sponsor Protocol Number: CS8663-A-E302 Start Date*: 2005-08-22
    Sponsor Name:Sankyo Pharma GmbH
    Full Title: EFFICACY AND SAFETY OF AMLODIPINE USED AS ADD-ON THERAPY IN MODERATELY TO SEVERELY HYPERTENSIVE PATIENTS NOT ADEQUATELY CONTROLLED BY OLMESARTAN MEDOXOMIL 20 MG MONOTHERAPY. Eficacia y seguridad de...
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.0 10015488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005925-31 Sponsor Protocol Number: LAC02 Start Date*: 2008-01-31
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF 6-MONTH ACETYLCARNITINE THERAPY ON ARTERIAL BLOOD PRESSURE, LIPID AND METABOLIC PROFILE, AND KIDNEY FUNCT...
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004212-21 Sponsor Protocol Number: AMAG-423-201 Start Date*: 2019-05-24
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Pree...
    Medical condition: Severe Preeclampsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10040444 Severe pre-eclampsia LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Temporarily Halted) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003547-23 Sponsor Protocol Number: DAR-312 Start Date*: 2007-11-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Grou...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) BE (Completed) DK (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:11:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA